Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: Practical aspects and outcome of motor and non-motor complications

Clinical Neuropharmacology

Volumn 31, Issue 3, 2008, Pages 151-166

  Eggert, Karla ^a,b   Schrader, Christoph ^b,c   Hahn, Michaela ^b,c   Stamelou, Maria ^a,b   Rüssmann, Anne ^b,d   Dengler, Reinhard ^b,c   Oertel, Wolfgang ^a,b   Odin, Per ^b,d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Competence Network on Parkinson's Disease ^*  (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Klinikum Bremerhaven Reinkenheide   (Germany)

Author keywords

Continuous dopaminergic stimulation; Jejunal infusion; Levodopa; Motor complications; Parkinson disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE;

ADULT; AGED; AKINESIA; ANXIETY; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISLOCATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INFECTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; OCCLUSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SYMPTOMATOLOGY;

ADULT; ANTIPARKINSON AGENTS; CATHETERIZATION; DYSKINESIAS; HUMANS; INTUBATION, GASTROINTESTINAL; JEJUNUM; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 44649127437     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e31814b113e     Document Type: Article

References (33)

1. Markham CH, Diamond SG. Long term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19:365-372.
2. Marsden C. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17:32-44.
3. De la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
4. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013-1038.
5. Clarke CE, Vieregge P, Ziegler M, et al. The impact of L-dopa-induced dyskinesias on patients' quality of life in Parkinson's disease: a prospective European study. Neurology 2002;58:A469.
6. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
7. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
8. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-353.
9. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-1850.
10. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-1241.
11. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in patients with Parkinson's disease. Neurology 1994;44:913-919.
12. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
13. Stocchi F, Vacca L, De Pandis MF, et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease. Long-term results. Neurol Sci 2001;22:93-94.
14. Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066.
15. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;21:412-415.
16. Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-265.
17. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
18. Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96.
19. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993;43:1698-1703.
20. Nyholm D Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
21. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
22. Syed N, Murphy J, Zimmerman T Jr, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
23. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 2001;104:343-348.
24. Chase TN. Levodopa therapy: consequences of the non-physiologic replacement of dopamine. Neurology 1998;50:17-25.
25. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47:22-34.
26. Nyholm D, Jansson R, Willows T, et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65:1506-1507.
27. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
28. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496.
29. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524-530.
30. Houeto JL, Mesnage V, Maller L, et al. Behavioral disorders, Parkinson's disease and subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-707.
31. Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006;66:1830-1836.
32. Morrison CE, Borod JC, Perrine K, et al. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 2004;19:165-181.
33. Trepanier LL, Kumar R, Lozano AM, et al. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn 2000;42:324-347.